Analysts kept Buy on Alnylam Pharmaceuticals (NASDAQ:ALNY) even as Bank of America and Truist cut 12‑month targets to $410 while HC Wainwright raised its target to $485; the company will report Q2 2026 results July 30 before the U.S. open with a conference call at 8:30 a.m. ET.
Previous Week Recap
- Alnylam Analyst Targets Updated: Three brokerages kept Buy on Alnylam (ALNY). Bank of America and Truist cut 12‑month targets to $410; HC Wainwright raised its target to $485. Updates reflect revised analyst valuations.
- Alnylam Q2 2026 Results Date: Alnylam (ALNY) will report Q2 2026 results for period ended June 30 on July 30 before U.S. open. Conference call at 8:30 a.m. ET with live webcast and archived replay.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.